<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064202</url>
  </required_header>
  <id_info>
    <org_study_id>NL78349029.21.</org_study_id>
    <nct_id>NCT05064202</nct_id>
  </id_info>
  <brief_title>Mechanical Left Ventricular Unloading in Acute Decompensated Heart Failure</brief_title>
  <acronym>UNLOAD-HF</acronym>
  <official_title>Use of mechaNical Left ventricuLar unlOading in Acute decompensateD Heart Failure; the UNLOAD-HF Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abiomed Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate whether initial temporary circulatory&#xD;
      support through the Impella CP® system in patients with acute decompensated heart failure&#xD;
      (ADHF) and in-hospital worsening heart failure (WHF) in whom inotropes are deemed necessary,&#xD;
      has the potential to reduce the heart failure related-clinical events compared to the current&#xD;
      standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate the efficacy of primary percutaneous mechanical left ventricular unloading&#xD;
      with the Impella CP® assist device in patients with acute decompensated heart failure (ADHF)&#xD;
      and in-hospital worsening heart failure (WHF) vs. current standard of care with inotropes as&#xD;
      first-line escalating therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality, mechanical ventillation, renal replacement therapy and rehospitalisation or urgent visit for heart failure (Efficay - Primary Combined Clinical Endpoint)</measure>
    <time_frame>baseline to 60 days</time_frame>
    <description>Number of patients suffering from any of: all-cause death, mechanical ventillation, renal replacement therapy and rehospitalisation or urgent hospital visit for heart failure up to 60 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary capillary wedge pressure (PCWP) and right arterial pressure (RAP) &lt; 30mmHg (Efficacy - Key Secondary Endpoint)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of patients achieving a combined PCWP (mmHg) and RAP (mmHg) below 30mmHg determined at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCWP(basline) - 25% (Efficacy - Key Secondary Endpoint)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of patients achieving a PCWP (mmHg) that has dropped 25% from baseline PCWP (mmHg) determined at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCWP(baseline) - 5mmHg (Efficacy - Key Secondary Endpoint)</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of patients achieving a PCWP (mmHg) that has dropped 5mmHg from baseline PCWP (mmHg) determined at 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that died of any cause during hospitalisation, up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventillation (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that were mechanically ventilated during hospitalisation, up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that received renal replacement therapy during hospitalisation, up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation or urgent hospital visit for heart failure (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that were hospitalised or had an urgent hospital visit for heart failure up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent / rescue MCS implantation (permanent) (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that received a permanent MCS device implantation up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation time (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to discharge, on average 15 days</time_frame>
    <description>Lenght of index hospitalisation for decompensated heart failure in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart transplantation (Efficacy - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that were transplanted up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or TIA (Safety - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that developed a stroke or TIA up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding (Safety - Secondary Endpoint)</measure>
    <time_frame>baseline to 1 year</time_frame>
    <description>Number of patients that developed a major bleed up to day 30, 60 and 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major vascular events (Safety - Device Related Secondary Endpoint)</measure>
    <time_frame>baseline to 30 days</time_frame>
    <description>Number of patients that developed a major vascular event up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb ischemia (Safety - Device Related Secondary Endpoint)</measure>
    <time_frame>baseline to 30 days</time_frame>
    <description>Number of patients that developed limb ischemia up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemolysis (Safety - Device Related Secondary Endpoint)</measure>
    <time_frame>baseline to 30 days</time_frame>
    <description>Number of patients diagnosed with hemolysis up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insertion site infection (Safety - Device Related Secondary Endpoint)</measure>
    <time_frame>baseline to 30 days</time_frame>
    <description>Number of patients that developed an infection at the insertion site up to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic valve injury (Safety - Device Related Secondary Endpoint)</measure>
    <time_frame>baseline to 30 days</time_frame>
    <description>Number of patients that developed aortic valve insufficiency (by echo) up to day 30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Impella CP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the experimental arm will be treated with an Impella CP (+/- standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ADHF-patients with in-hospital WHF in whom escalation therapy with inotropes is deemed necessary and who are in the control arm will be treated with inotropes (standard of care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella CP</intervention_name>
    <description>percutaneous Mechanical Circulatory Support (pMCS), percutaneous Left Ventricular Assist Device (pLVAD)</description>
    <arm_group_label>Impella CP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inotropes</intervention_name>
    <description>Enoximone, Dobutamine, Dopamine, Milrinone</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of HFrEF according to ESC HF guidelines, preferably LVEF ≤ 35%&#xD;
&#xD;
          2. Evidence of in-hospital worsening heart failure requiring escalation of inotropic&#xD;
             therapy according to the treating heart failure cardiologist based on at least 3 / 4&#xD;
             predefined hemodynamic and clinical criteria&#xD;
&#xD;
          3. No previous episodes of inotropic treatment during current admission or within the&#xD;
             last month&#xD;
&#xD;
          4. Age: 18 - 80 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications for Impella CP&#xD;
&#xD;
          2. Severe concomitant RV failure&#xD;
&#xD;
          3. Grade IV mitral regurgitation eligible for surgical treatment&#xD;
&#xD;
          4. Contraindications for inotropic usage&#xD;
&#xD;
          5. Dialysis for end-stage renal failure&#xD;
&#xD;
          6. Acute coronary syndrome&#xD;
&#xD;
          7. History of CVA or TIA within previous 90 days&#xD;
&#xD;
          8. History of acute myocardial infarction within previous 30 days&#xD;
&#xD;
          9. History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombo-cytopenia), any recent GU or GI bleed, or will refuse blood transfusions&#xD;
&#xD;
         10. Inflammatory&#xD;
&#xD;
         11. Active systemic infections&#xD;
&#xD;
         12. Acute myocarditis&#xD;
&#xD;
         13. Active on transplant waiting list&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Nap, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Nap, MD PhD</last_name>
    <phone>+31(0)614102081</phone>
    <email>a.nap@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academical Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose PS Henriques, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center (VUMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander Nap, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerity Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric Lipsic, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum (LUMC)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Jose Montero-Cabezas, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center (ErasmusMC)</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas van Mieghem, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Alexander Nap</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Unloading</keyword>
  <keyword>In-hospital Worsening Heart Failure (WHF)</keyword>
  <keyword>percutaneous Left Ventricular Assist Device (pLVAD)</keyword>
  <keyword>percutaneous Mechanical Circulatory Support (pMCS)</keyword>
  <keyword>Inotropes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

